文献速递淋巴瘤

苯达莫司汀单药治疗中国复发或难治性B细胞非霍奇金淋巴瘤患者:一项Ⅱ期、前瞻性、多中心、单臂研究

[Bendamustine monotherapy for Chinese patient treatment with relapsed or refractory B cell non-Hodgkin lymphoma: a phase Ⅱ, prospective, multicenter, single-arm study].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

该前瞻性、多中心、开放标签、单臂Ⅱ期研究纳入2012年3月至2016年12月国内11所医院78例复发/难治B细胞非霍奇金淋巴瘤患者,评估苯达莫司汀单药的有效性和安全性。全分析集客观缓解率61.5%,完全缓解率5.1%,中位无进展生存期8.7个月,中位总生存期25.5个月。结论认为苯达莫司汀单药治疗复发/难治B-NHL患者有良好的疗效和安全性。

要点

  • 全分析集客观缓解率61.5%,完全缓解率5.1%,中位缓解持续时间8.3个月。
  • 中位无进展生存期8.7个月,中位总生存期25.5个月,中位随访33.6个月。
  • 治疗<4个周期是影响无进展生存期的预后不良因素(P=0.003)。

核心结论

  • 苯达莫司汀单药治疗复发/难治B细胞非霍奇金淋巴瘤患者有良好的疗效和安全性。

研究设计与样本

  • 前瞻性、多中心、开放标签、单臂Ⅱ期临床研究。
  • 纳入2012年3月至2016年12月国内11所医院78例接受苯达莫司汀治疗的B细胞非霍奇金淋巴瘤患者。

主要发现

  • 患者中位年龄58(24~76)岁,69例(88.4%)为Ⅲ/Ⅳ期,61例(78.2%)对末线治疗耐药。
  • 全组患者中位接受4(1~10)个周期苯达莫司汀治疗。
  • 全分析集客观缓解率61.5(95%CI 49.8~72.3)%,完全缓解率5.1(95%CI 1.4~12.6)%。
  • 中位随访33.6(95%CI 17.4~38.8)个月,中位缓解持续时间8.3(95%CI 5.5~14.0)个月,中位无进展生存期8.7(95%CI 6.7~13.2)个月,中位总生存期25.5个月(95%CI 14.2个月~未达到)。
  • 最常见的3~4级血液学不良反应为淋巴细胞减少(74.4%)、中性粒细胞减少(52.6%)、白细胞减少(39.7%)、血小板减少(29.5%)和贫血(15.4%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of bendamustine monotherapy in Chinese patients with relapsed/refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL) . Methods: This prospective, multicenter, open label, single-arm, phase Ⅱ study investigated bendamustine's efficacy and safety in Chinese patients with R/R B-NHL. A total of 78 patients with B-NHL in 11 hospitals in China from March 2012 to December 2016 were included, and their clinical characteristics, efficacy, and survival were analyzed. Results: The median age of all patients was 58 (range, 24-76) years old, and 69 (88.4% ) patients had stage Ⅲ/Ⅳ disease. 61 (78.2% ) patients were refractory to previous treatments. Patients received a median of 4 (range, 1-10) cycles of bendamustine treatment. The overall response rate was 61.5 (95% CI 49.8-72.3) % , the median response duration was 8.3 (95% CI 5.5-14.0) months, and the complete remission (CR) rate was 5.1 (95% CI 1.4-12.6) % . In the full analysis set, median progression-free survival (PFS) and median OS were 8.7 (95% CI 6.7-13.2) months and 25.5 months (95% CI 14.2 months to not reached) , respectively, after a median follow-up of 33.6 (95% CI 17.4-38.8) months. Lymphopenia (74.4% ) , neutropenia (52.6% ) , and leukopenia (39.7% ) , thrombocytopenia (29.5% ) and anemia (15.4% ) were the most common grade 3-4 hematologic adverse events (AE) . The most frequent non-hematologic AEs included nausea (43.6% ) , vomiting (33.3% ) , and anorexia (29.5% ) . Univariate and multivariate analysis showed that <4 cycles of bendamustine treatment was a poor prognostic factor for PFS (P=0.003) , and failure to accept fludarabine containing regimen was a poor prognostic factor for OS (P=0.009) . Conclusion: Bendamustine monotherapy has good efficacy and safety in the treatment of patient with R/R B-NHL. 目的: 评估苯达莫司汀单药治疗中国复发/难治B细胞非霍奇金淋巴瘤(B-NHL)患者的有效性和安全性。 方法: 本研究为前瞻性、多中心、开放标签、单臂Ⅱ期临床研究。纳入2012年3月至2016年12月国内11所医院78例接受苯达莫司汀治疗的B-NHL患者,分析患者的临床特征、疗效及生存。 结果: 患者的中位年龄为58(24~76)岁,69例(88.4%)患者为Ⅲ/Ⅳ期,61例(78.2%)患者对末线治疗耐药。全组患者中位接受4(1~10)个周期苯达莫司汀治疗。全分析集中,客观缓解率为61.5(95% CI 49.8~72.3)%,完全缓解率为5.1(95%CI 1.4~12.6)%。中位随访33.6(95%CI 17.4~38.8)个月,中位缓解持续时间为8.3(95%CI 5.5~14.0)个月,中位无进展生存(PFS)期和中位总生存(OS)期分别为8.7(95%CI 6.7~13.2)个月和25.5个月(95%CI 14.2个月~未达到)。最常见的3~4级血液学不良反应为淋巴细胞减少(74.4%)、中性粒细胞减少(52.6%)、白细胞减少(39.7%)、血小板减少(29.5%)和贫血(15.4%)。最常见的非血液学不良反应为恶心(43.6%)、呕吐(33.3%)和厌食(29.5%)。多因素分析显示,苯达莫司汀治疗<4个周期是影响PFS的预后不良因素(P=0.003),既往未接受含氟达拉滨方案是影响OS的预后不良因素(P=0.009)。 结论: 苯达莫司汀单药治疗复发难治B-NHL患者有良好的疗效和安全性。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Gao Y, Yang Y, Cen H, et al. [Bendamustine monotherapy for Chinese patient treatment with relapsed or refractory B cell non-Hodgkin lymphoma: a phase Ⅱ, prospective, multicenter, single-arm study]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 36709185. doi:10.3760/cma.j.issn.0253-2727.2022.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。